pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

verve-therapeutics PRESS RELEASE ARCHIVE

Jun 16, 2021

Verve Therapeutics Announces Pricing of Initial Public Offering

Jun 1, 2021

Verve Therapeutics Appoints Leading Biotechnology Executive Michael MacLean to its Board of Directors

May 19, 2021

Verve Therapeutics Announces Nature Publication Highlighting its Use of Base Editing to Potently and Durably Lower Blood PCSK9 and LDL-C in Non-Human Primates

May 11, 2021

Verve Therapeutics to Present Preclinical Data from Gene Editing Programs for the Treatment of Atherosclerotic Cardiovascular Disease at ASGCT

May 5, 2021

Verve Therapeutics Appoints Industry Leader Sheila Mikhail to its Board of Directors

Mar 12, 2021

Altasciences Conducts Preclinical Studies in Support of Verve Therapeutics’ Gene Editing Approach for Cardiovascular Disease

Jan 19, 2021

Verve Therapeutics Secures $94 Million in Series B Financing to Advance Pipeline of Gene Editing Medicines for Cardiovascular Disease

Jan 12, 2021

Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates

Jan 6, 2021

Verve Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Nov 23, 2020

Verve Therapeutics to Present at the Piper Sandler Annual Virtual Healthcare Conference

Nov 9, 2020

Verve Therapeutics Announces Presentations on its Gene Editing Approach to Develop Transformative Medicines for Coronary Heart Disease at the American Heart Association Scientific Sessions 2020

Sep 25, 2020

Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit

Aug 13, 2020

Verve Therapeutics to Participate in Oppenheimer’s Private Life Sciences Company Call Series

Jun 27, 2020

Verve Therapeutics Presents New Data in Non-Human Primates Validating Gene Editing as a Treatment Approach for Coronary Heart Disease at the ISSCR 2020 Virtual Annual Meeting

Jun 17, 2020

Verve Therapeutics CEO Sekar Kathiresan, M.D., to Give Keynote Presentation at the International Society for Stem Cell Research (ISSCR) 2020 Virtual Annual Meeting

Jun 11, 2020

Verve Therapeutics Raises $63 million in Series A2 Financing to Advance Gene-Editing Therapies for Heart Disease

Oct 3, 2019

Verve Therapeutics Appoints Cardiologist Andrew Bellinger, M.D., Ph.D., as Chief Scientific Officer

Oct 2, 2019

Verve Therapeutics to Present at the 2019 Jefferies Gene Therapy/Editing Summit

Sep 16, 2019

Verve Therapeutics Appoints Drug Delivery Expert Andrew Geall, Ph.D., to Scientific Advisory Board

May 7, 2019

Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

Google Analytics Alternative